Navigation Links
John A. MacPhee Resigns From Strativa Pharmaceuticals
Date:12/17/2010

WOODCLIFF LAKE, N.J., Dec. 17, 2010 /PRNewswire-FirstCall/ -- Par Pharmaceutical Companies, Inc. (NYSE: PRX) announced today that John A. MacPhee, has resigned his positions as President of Strativa Pharmaceuticals and Executive Vice President of Par Pharmaceutical Companies to pursue other interests effective January 31, 2011.  Patrick G. LePore, Par Pharmaceutical Companies, Chairman, CEO and President, will assume day-to-day oversight of Strativa on an interim basis.

Patrick G. LePore states, "In six years, John has successfully built a valuable platform and product portfolio that establishes Strativa as one of the best positioned young specialty companies in the industry.  I thank him for his many contributions and wish him well in his future pursuits."  Mr. LePore continues, "We remain fully committed to the business model and to driving growth in both our generic and branded divisions."

About Strativa Pharmaceuticals

Strativa Pharmaceuticals, the proprietary products division of a wholly owned subsidiary of Par Pharmaceutical Companies, Inc. (NYSE: PRX), excels at finding, enhancing, and bringing to market drugs that make a meaningful difference to patients. For more information about Strativa, visit www.strativapharma.com.

About Par Pharmaceutical Companies

Par Pharmaceutical Companies, Inc. is a U.S.-based specialty pharmaceutical company.  Through its wholly owned subsidiary's two operating divisions, Par Pharmaceutical and Strativa Pharmaceuticals, it develops, manufactures and markets higher-barrier-to-entry generic drugs and niche, innovative proprietary pharmaceuticals.  For press releases and other company information, visit www.parpharm.com.

Safe Harbor Statement

Certain statements in this news release constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995.  To the extent any statements made in this news release contain information that is not historical, these statements are essentially forward-looking and, as such, are subject to known and unknown risks, uncertainties and contingencies, many of which are beyond the control of the Company, which could cause actual results and outcomes to differ materially from those expressed herein.  Risk factors that might affect such forward-looking statements include those set forth in Item 1A of the Company's most recent Annual Report on Form 10-K, in other of the Company's filings with the SEC from time to time, including Quarterly Reports on Form 10-Q and Current Reports on Form 8-K, and on general industry and economic conditions.  Any forward-looking statements included in this news release are made as of the date hereof only, based on information available to the Company as of the date hereof, and, subject to any applicable law to the contrary, the Company assumes no obligation to update any forward-looking statements.


'/>"/>
SOURCE Par Pharmaceutical Companies, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Paul D. Duke Resigns From Mesas Board of Directors
2. Strativa Pharmaceuticals Signs Agreement With Swedish Orphan Biovitrum Regarding Nascobal®
3. FDA Approves Strativa Pharmaceuticals Zuplenz® (ondansetron) Oral Soluble Film
4. Strativa Pharmaceuticals Provides An Update On Zuplenz(R) (Ondansetron) Oral Soluble Film
5. Strativa Pharmaceuticals Development Partner, BioAlliance Pharma, Presents Phase III Study Results of Miconazole Lauriad(R) for the Treatment of Oropharyngeal Candidiasis
6. Strativa Pharmaceuticals Provides Product Pipeline Update
7. Strativa Pharmaceuticals Announces Preliminary Results from ONCONASE(R) Phase IIIb Clinical Trial
8. Strativa Pharmaceuticals Announces Phase III Results for Loramyc(R) to Treat Oropharyngeal Candidiasis
9. Poniard Pharmaceuticals Announces Plan for Voluntary Prepayment of Term Loan and Transfer to Nasdaq Capital Market
10. Savient Pharmaceuticals to Present at the 29th Annual J.P. Morgan Healthcare Conference
11. Amira Pharmaceuticals Announces the Nomination of an Orally Available Pre-Clinical Candidate in a New LPA-Related Program, an Autotaxin Inhibitor
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... NEW YORK , March 29, 2017 ... ... society and the public safety in regulating marijuana, but economic ... revenues, job creation, and reduced law enforcement costs. However, to ... like those provided by SinglePoint, Inc. (OTC: SING) ( SING ...
(Date:3/29/2017)... , March 29, 2017 Neurim Pharmaceuticals ... Exeltis will obtain exclusive marketing rights for Neurim,s new Rx PedPRM ... ... targeted to treat sleep disorders in children with Autism Spectrum Disorders ... sleep medication approved for children. The collaboration with Exeltis ...
(Date:3/29/2017)... , March 29, 2017 /PRNewswire/ - Medicure Inc. ... release financial results for the year ended December ... 26, 2017. The results are being released later ... financial statements will include the operations and balances ... 1, 2016.  This release and filing date meets ...
Breaking Medicine Technology:
(Date:3/28/2017)... (PRWEB) , ... March 28, 2017 , ... ... Technology™, is the first technology to directly address the resolution to globally reduce ... Technology™ is a patented compound of FDA and TTB approved ingredients that when ...
(Date:3/28/2017)... ... March 28, 2017 , ... Resoundant, ... be invited to the Siemens Healthineers annual customer education symposium, a world-class learning ... take place from March 27 - 31, 2017 at the Atlanta Marriott Marquis ...
(Date:3/28/2017)... ... 2017 , ... The Thyroid Secret is a specialized 9-part ... program was recently launched on March 1, and Dr. Wentz discussed varied benefits ... Dr. Izabella Wentz is a licensed pharmacist and a foremost thyroid specialist. After ...
(Date:3/28/2017)... , ... March 28, 2017 , ... ... share of all holidays (IBT World Travel Trends Report). As travelers visit both ... a range in temperatures, and prolonged sun exposure. In response, the outdoor industry ...
(Date:3/28/2017)... San Mateo, CA (PRWEB) , ... ... ... Radiosurgery Society (RSS), a non-profit medical society dedicated to advancing the science ... manuscript leveraging data from its RSSearch Patient Registry, a multi-institutional, observational registry ...
Breaking Medicine News(10 mins):